Quoin Pharmaceuticals Ltd. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Quoin Pharmaceuticals Ltd. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $5.48M, a 6.27% decline year-over-year.
- Quoin Pharmaceuticals Ltd. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $5.85M.
- Quoin Pharmaceuticals Ltd. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $14.90M.
- Quoin Pharmaceuticals Ltd. stock issued during period, value, new issues for fiscal 2025 was $15.08M, a 34.13% increase from fiscal 2024.
- Quoin Pharmaceuticals Ltd. stock issued during period, value, new issues for fiscal 2024 was $11.24M, a 92.23% increase from fiscal 2023.
- Quoin Pharmaceuticals Ltd. stock issued during period, value, new issues for fiscal 2023 was $5.85M, a 60.68% decline from fiscal 2022.
- Quoin Pharmaceuticals Ltd. stock issued during period, value, new issues for fiscal 2022 was $14.88M, a 12.49% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $15.08M 10-K · filed 2026-03-26 | |
| 2024-12-31 | $11.24M 10-K · filed 2026-03-26 | |
| 2024-03-31 | $5.48M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $5.85M 10-K · filed 2025-03-13 | |
| 2023-03-31 | $5.85M 10-Q · filed 2024-11-08 | |
| 2022-12-31 | $14.88M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $14.90M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $17.00M 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |